<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116089</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0908-PR-0029</org_study_id>
    <secondary_id>2009-016780-11</secondary_id>
    <nct_id>NCT01116089</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer</brief_title>
  <official_title>PHARMACOKINETIC STUDY OF BRAMITOB® ADMINISTERED FOR INHALATION BY PARI eFLOW® RAPID ELECTRONIC NEBULIZER VS PARI LC® PLUS NEBULIZER COUPLED WITH THE PARI TURBO BOY® N COMPRESSOR IN CYSTIC FIBROSIS PATIENTS INFECTED WITH PSEUDOMONAS AERUGINOSA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess pharmacokinetic and safety comparability of Bramitob®
      when administered for inhalation by using PARI eFlow® rapid electronic nebulizer vs PARI LC®
      PLUS nebulizer in Cystic Fibrosis Patients infected with Pseudomonas Aeruginosa
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma tobramycin pharmacokinetic parameters (Cmax and AUC0-t) after twice daily inhalation of Bramitob® using PARI eFlow® nebulizer vs PARI LC® PLUS nebulizer</measure>
    <time_frame>on day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma tobramycin pharmacokinetic parameters (Cmax, tmax and AUC0-t) after inhalation of Bramitob® using PARI eFlow® nebulizer vs PARI LC® PLUS nebulizer</measure>
    <time_frame>on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum tobramycin pharmacokinetic parameters (Cmax, tmax and AUC0-t) after inhalation of Bramitob® using PARI eFlow® nebulizer vs PARI LC® PLUS nebulizer</measure>
    <time_frame>on day 1 and on day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation of tobramycin in plasma and sputum after repeated doses calculated as the ratio: AUC0-t DAY 28 / AUC0-t DAY 1 and Cmax DAY 28 / Cmax DAY 1</measure>
    <time_frame>day 1 - day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by adverse events, adverse drug reactions, incidence of bronchospasm, laboratory parameters, physical examination, body weight, vital signs results</measure>
    <time_frame>day1-day28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with minimum plasma tobramycin levels Cmin &gt; 2mcg/mL and maximum plasma tobramycin levels Cmax &gt; 12 mcg/mL</measure>
    <time_frame>on day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time necessary for the nebulization of the dose</measure>
    <time_frame>on day 1 and on day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>PARI LC® PLUS nebulizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PARI eFlow® rapid electronic nebulizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bramitob® administered by PARI LC® PLUS nebulizer</intervention_name>
    <description>(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days</description>
    <arm_group_label>PARI LC® PLUS nebulizer</arm_group_label>
    <other_name>Bramitob®, Tobrineb®, Actitob®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bramitob® administered by PARI eFlow® rapid electronic nebulizer</intervention_name>
    <description>(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days</description>
    <arm_group_label>PARI eFlow® rapid electronic nebulizer</arm_group_label>
    <other_name>Bramitob®, Tobrineb®,Actitob®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          -  Patients of either sex aged ≥ 18 years;

          -  Clinical diagnosis of cystic fibrosis (patients registered in the National Registry of
             cystic fibrosis or other documents, if applicable, depending on country legislation);

          -  Positive response (sweat chloride concentration ≥ 60 mmol/l) in the standard sweat
             test documented in the clinical records or sweat chloride concentration ≥ 40 mmol/l
             and at least two gene mutations consistent with CF documented in the clinical records;

          -  Chronic colonization of Pseudomonas aeruginosa

          -  FEV1 ≥ 35% of the predicted normal value calculated according to the recommendation of
             the Official Statement of the European Respiratory Society and American Thoracic
             Society

        Main exclusion Criteria:

          -  Evidence of impaired renal function (serum creatinine level ≥ 1.5 mg/dl);

          -  Evidence of impaired auditory function (auditory threshold in either ear above 20 dB
             at frequencies between 250 and 8000Hz);

          -  Sputum culture containing Burkholderia cepacia;

          -  Received loop diuretics within 7 days before study drug administration;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jozef Ružička, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakultná nemocnica s poliklinikou Bratislava, Slovakia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrej Somos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of L. Pasteur, Pneumonology Department, Rastislavova 43, 041 90, Kosice, Slovakia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jana Skřičková, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Brno Bohunice, Jihlavská 20, 625 00, Brno, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Beresova, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital with Health Center, F.D. Roosevelta Banská Bystrica, L. Svoboda´s square 1, 975 17, Banská Bystrica, Slovakia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Svetlana Şciuca, M.D, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMSI Institude of Cardiology, MD-2025, 29/1 Testimitanu str., Chisinau, Republic of Moldova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Brno Bohunice</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMSI Institude of Cardiology</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital with Health Center</name>
      <address>
        <city>Banská Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultná nemocnica s poliklinikou Bratislava (FNsP)</name>
      <address>
        <city>Brastislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of L. Pasteur, Pneumonology Department</name>
      <address>
        <city>Kosice</city>
        <zip>041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Moldova, Republic of</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis, tobramycin,nebulizer, PK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

